Recombinant herpes zoster vaccine not checked
Shanghai Institute Of Biological Products
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Adjuvant control 1, Dose Level 1, Intramuscular injection, 0, 2 months schedule”In the company’s words, NCT06932523 on ClinicalTrials.gov
- Tested for
- Herpes Zoster (HZ)
- Main trialPhase 1/2
- “The purpose of this clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy individuals aged 40 years and above. This study will be conducted in 2 substudies: Substudy A (Phase I) and Substudy B (Phase Ⅱ).”In the company’s words, NCT06932523 on ClinicalTrials.gov
Other drugs for Herpes Zoster (HZ)
- HZ/su vaccineGSK · Phase 3
- Recombinant Zoster VaccineMAXVAX Biotechnology Limited Liability Company · Phase 3
- CVI-VZV-001Aribio Lab Co., Ltd. · Phase 2
- SYS6017CSPC · Phase 2
- Z-1018Dynavax Technologies Corporation · Phase 1/2
- SYS6052CSPC · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 30 Jun 2026 | A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026